Loading
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
  • Log In
    • Register
Contacts us @ MediPr.org
Medical Writer Agency | 醫學作家香港 | 醫學寫作 | MediPR | MediPaper Hong Kong
  • MDnews
  • About [‘mediPr]
  • Search
  • Menu Menu

Non-Sponsored Content

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail


Cardiovascular Disease

Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety

By: News Feed | Last updated: 29th August 2018 | In: Cardiovascular

Article Keywords

AF, atrial fibrillation, Daiichi Sankyo, edoxaban, factor Xa, Lixiana, warfarin

Real-life use of edoxaban (Lixiana®, Daiichi Sankyo) in Asian atrial fibrillation (AF) patients significantly lowered the risk of ischaemic stroke (IS), intracranial haemorrhage (ICH), hospitalisation for gastrointestinal (GI) bleeding, hospitalisation for major bleeding, and all-cause death when compared to warfarin. This was concluded by the Korean investigators in the Journal of the American College of Cardiology. The benefits were consistent in the various high-risk subgroups.

The study registered new AF patients with prescriptions for either edoxaban (n=4,200) or warfarin (n=31,565) from the Korean National Health Insurance Service database. A propensity score matching method for edoxaban vs warfarin users balanced the covariates across the groups. The investigators analysed the risk of IS, ICH, hospitalisation for GI or major bleeding, and all-cause death.

The 1:3 propensity score−matched cohort of Korean AF patients encompassed 4,061 edoxaban and 12,183 warfarin users. Baseline characteristics were balanced between the two groups for age and CHA2DS2-VASc score (score 3).

Use of edoxaban was associated with a significantly decreased risk of IS (HR=0.693; 95% CI, 0.487-0.959), ICH (HR=0.407; 95% CI, 0.182-0.785), hospitalisation for GI bleeding (HR=0.597; 95% CI, 0.363-0.930), hospitalisation for major bleeding (HR=0.532; 95% CI, 0.352-0.773), and all-cause death (HR=0.716; 95% CI, 0.549-0.918) when compared to warfarin. Moreover, the improved clinical outcomes with edoxaban vs warfarin were consistent across all subgroups (age, sex, CHA2DS2-VASc score, renal function, edoxaban dose).

References

Lee SR, et al. J Am Coll Cardiol 2018: DOI: 10.1016/j.jacc.2018.05.066


Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Newsletter Sign-Up


YOU MAY ALSO LIKE

COVID-19 impacting regular patient care for cardiovascular diseases

COVID-19 impacting regular patient care for cardiovascular diseases

https://medi-paper.com/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282021-03-02 17:48:19COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

https://medi-paper.com/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562021-03-02 17:48:11SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

https://medi-paper.com/wp-content/uploads/2021/02/Registry-data-shows-early-and-large-LDL-reductions-are-associated-with-lowest-post-MI-cardiovascular-event-rates.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 10:35:042021-03-02 17:48:07Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

https://medi-paper.com/wp-content/uploads/2020/10/data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 16:12:402020-10-12 16:01:55Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
PreviousNext
COVID-19 impacting regular patient care for cardiovascular diseases
17th February 2021

COVID-19 impacting regular patient care for cardiovascular diseases

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
10th February 2021

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

© Copyright 2018 MediPaper Medical Communications Ltd. – Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety.

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail

YOU MAY ALSO LIKE

COVID-19 impacting regular patient care for cardiovascular diseases

COVID-19 impacting regular patient care for cardiovascular diseases

https://medi-paper.com/wp-content/uploads/2021/02/COVID-19-impacting-regular-patient-care-for-cardiovascular-diseases.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-17 11:52:282021-03-02 17:48:19COVID-19 impacting regular patient care for cardiovascular diseases
SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy

https://medi-paper.com/wp-content/uploads/2021/02/SARS-CoV-2-infection-in-children-and-an-increased-risk-of-thrombotic-microangiopathy.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 15:41:562021-03-02 17:48:11SARS-CoV-2 infection in children and an increased risk of thrombotic microangiopathy
Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates

https://medi-paper.com/wp-content/uploads/2021/02/Registry-data-shows-early-and-large-LDL-reductions-are-associated-with-lowest-post-MI-cardiovascular-event-rates.jpg 1024 1918 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-02-10 10:35:042021-03-02 17:48:07Registry data shows early and large LDL reductions are associated with lowest post-MI cardiovascular event rates
data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia

Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia

https://medi-paper.com/wp-content/uploads/2020/10/data-for-safe-and-effective-use-of-evolocumab-in-paediatric-familial-hypercholesterolaemia.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 16:12:402020-10-12 16:01:55Data for safe and effective use of evolocumab in paediatric familial hypercholesterolaemia
psoriasis-biologics-may-help-reduce-coronary-plaque

Psoriasis biologics may help reduce coronary plaque

https://medi-paper.com/wp-content/uploads/2020/10/psoriasis-biologics-may-help-reduce-coronary-plaque.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:45:112020-10-12 17:55:31Psoriasis biologics may help reduce coronary plaque
ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients

Ticagrelor may not confer post-MI benefits to elderly patients

https://medi-paper.com/wp-content/uploads/2020/10/ticagrelor-may-not-confer-post-mi-benefits-to-elderly-patients.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-10-08 15:05:532020-10-12 16:00:51Ticagrelor may not confer post-MI benefits to elderly patients
Evidence-of-SARS-CoV2-in-heart-cells

Evidence of SARS-CoV2 in heart cells

https://medi-paper.com/wp-content/uploads/2020/09/Evidence-of-SARS-CoV2-in-heart-cells.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-09-22 10:19:272020-09-24 12:33:04Evidence of SARS-CoV2 in heart cells
risk-of-thrombosis-with-sars-cov-2-infection

Risk of thrombosis with SARS-CoV-2 infection

https://medi-paper.com/wp-content/uploads/2020/08/risk-of-thrombosis-with-sars-cov-2-infection-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-27 16:33:072020-09-24 12:37:30Risk of thrombosis with SARS-CoV-2 infection
further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure

Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results

https://medi-paper.com/wp-content/uploads/2020/08/further-analyses-of-dapa-hf-shows-dapagliflozin-leads-to-fewer-outpatient-heart-failure-scaled.jpg 1024 1818 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-25 14:40:232020-09-01 17:02:10Class effect of SGLT2 inhibitors on heart failure reduction solidified with dapagliflozin and empagliflozin results
potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations

Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations

https://medi-paper.com/wp-content/uploads/2020/08/potential-protective-effects-of-the-influenza-vaccine-on-cardiovascular-outcomes-in-high-risk-populations-scaled.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-08-13 15:28:132020-08-17 16:56:09Potential protective effects of the influenza vaccine on cardiovascular outcomes in high-risk populations
Somazina citicoline small vessel disease vascular cognitive impairment traumatic brain injury neuroimaging cerebrovascular disorders ischaemic haemorraghic stroke rehabilitation neuroprotection

Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease

https://medi-paper.com/wp-content/uploads/2019/12/Somazina-citicoline-small-vessel-disease-vascular-cognitive-impairment-traumatic-brain-injury-neuroimaging-cerebrovascular-disorders-ischaemic-haemorraghic-stroke-rehabilitation-neuroprotection.png 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2019-12-16 10:35:082020-04-21 11:36:03Highlights of the 8th Asia Pacific Symposium on Cerebrovascular Disease
Prof. Stephen Chan i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier

I-O in Special Populations: Chronic Viral Hepatitis Carriers

https://medi-paper.com/wp-content/uploads/2018/07/Prof.-Stephen-Chan-i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2018-11-18 21:51:462018-12-17 14:08:24I-O in Special Populations: Chronic Viral Hepatitis Carriers
TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

https://medi-paper.com/wp-content/uploads/2018/09/TAVR-transcatheter-aortic-valve-replacement-with-Portico-valve-reduces-severe-aortic-stenosis-in-real-world-study-PORTICO-1-e1538119953610.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 15:23:462018-10-17 11:15:20Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study
TAVR vs SAVR - Transcatheter- vs surgical aortic valve replacement in high-risk patients 5-years survival

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

https://medi-paper.com/wp-content/uploads/2018/09/TAVR-vs-SAVR-Transcatheter-vs-surgical-aortic-valve-replacement-in-high-risk-patients-5-years-survival.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-28 12:43:062018-10-17 11:13:32Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

Anti-coagulation: impact on long-term mortality and early valve dysfunction

https://medi-paper.com/wp-content/uploads/2018/09/cv7.jpg 905 1280 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-09-19 10:30:462018-09-19 20:45:35Anti-coagulation: impact on long-term mortality and early valve dysfunction

Febuxostat prevents CV events in hyperuricaemia patients

https://medi-paper.com/wp-content/uploads/2018/08/cv4.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-08-29 11:32:012018-10-04 14:52:10Febuxostat prevents CV events in hyperuricaemia patients

Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety

https://medi-paper.com/wp-content/uploads/2018/08/cv1.jpg 1000 1500 News Feed https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png News Feed2018-07-30 09:51:512018-08-30 10:05:16Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety
asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

https://medi-paper.com/wp-content/uploads/2016/05/asco-2016-nivolumab.jpg 1000 1500 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-05-29 00:44:422018-05-11 17:25:59ASCO16 Nivolumab (Opdivo©) Data
asco 2016 immune checkpoint inhibitors

ACC2016: 8½ Important Cardiology Lessons Learned

https://medi-paper.com/wp-content/uploads/2016/04/acc2016-chicago-take-away-messages.jpg 1024 1536 Stijn van den Borne, MSc https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Stijn van den Borne, MSc2016-04-04 22:11:202017-11-25 14:09:33ACC2016: 8½ Important Cardiology Lessons Learned
PreviousNext
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply Cancel reply

You must be logged in to post a comment.

© Copyright 2018 MediPaper Medical Communications Ltd. – Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety.

Therapeutic Areas

Login

or
Login with Google
Login with Facebook
Login with Twitter
Login with LinkedIn
  • Register
  • Lost your password?

Or, sign up for our newsletter


 MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | PMHub
© 2016-2021 MediPaper Medical Communications Ltd. | Website by [’mediPr] | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • Pinterest
  • Youtube
  • Mail
  • Rss
Febuxostat prevents CV events in hyperuricaemia patients Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients Plasma TMB predicts response to atezolizumab in NSCLC patients
Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Accept settingsHide notification only
Copy link
CopyCopied
Powered by Social Snap
MediPaper Medical Communications Agency Hong Kong Blog